Distribution of carcinoma subtypes in 70 patients with carcinoma ex pleomorphic adenoma1:
Adenocarcinoma NOS |
31 |
Salivary duct carcinoma |
24 |
Adenosquamous carcinoma |
5 |
Undifferentiated carcinoma |
3 |
Adenoid cystic carcinoma |
3 |
Myoepithelial carcinoma |
2 |
Epithelial-myoepithelial carcinoma |
1 |
Sarcomatoid carcinoma |
1 |
Immunohistochemistry
67/691, 11/115 |
|
65/691, 11/115 |
|
9/691, 0/115 |
|
59/691 |
|
52/691 |
|
36/691 |
|
20/691 |
|
Actin |
5/691 |
2/691 |
|
28/691 |
|
c-erbB-2 |
21/691 |
Cyclin A may be helpful in the identification of CXPA:
|
Cyclin A |
|||
Pleomorphic adenoma |
CXPA |
|||
Normal duct and acinar epithelium |
0/284 |
0/124 |
||
Benign epithelium |
11/284 |
5/104 |
||
Benign stroma |
10/284 |
2/104 |
||
Malignant epithelium |
N/A |
12/144 |
||
Cytogenetics
CXPA commonly shows alterations of chromosome 8q21 and 12q13-15, as in the parent tumour. Loss of heterozygocisy at 12q may be a marker of potential for malignant transformation in pleomophric adenoma. Alterations of p53 and over-expression of c-erbB2 are common in CXPA3.
Prognosis
Prognostic factors include the extent of invasion beyond the capsule; in some papers 5 to 8 mm has been the critical extent. In the current WHO classification, tumour with invasion of less than 1.5 mm beyond the capsule are considered minimally invasive. Intracapsular and minimally invasive CXPA have almost no malignant potential2.
References
2 Perez-Ordonez B. Selected topics in salivary gland tumour pathology. Current Diagnostic Pathology2003;9:355-365.
3 Cheuk W,Chan JK. Advances in salivary gland pathology. Histopathology 2007; 51:1-20
This page last revised 4.8.2007.
©SMUHT/PW Bishop